(Q47687541)

English

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

clinically isolated syndrome

1 reference

based on heuristic

inferred from title

author name string

P O'Connor

1

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

R P Kinkel

2

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

M Kremenchutzky

3

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

publication date

1 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

15

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

6

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

728-734

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458509103173

21 January 2018

Identifiers

10.1177/1352458509103173

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19482863

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47687541&oldid=2165823310"